CVS Health Option Alert: Sep 19 $60 Puts at the Ask: 4250 vs 14089 OI; Earnings 7/31 Before Open 

CVS Health Option Alert: Sep 19 $60 Puts at the Ask: 4250 @ $3.14 vs 14089 OI; Earnings 7/31 Before Open Ref=$59.67

CVS Health Option Alert: Jan, 2027 $65 Calls Sweep (32) near the Ask: 666 vs 3386 OI; Earnings 7/31 Before Open 

CVS Health Option Alert: Jan, 2027 $65 Calls Sweep (32) near the Ask: 666 @ $8.2 vs 3386 OI; Earnings 7/31 Before Open Ref=$62.005

CVS Health (NYSE:CVS) Azioni

CVS HEALTH CORP

CVS Health

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.

Pfizer Covid shot

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ABBV

Gli esperti puntano su tre colossi farmaceutici per una rendita passiva. L&#39;analisi dei titoli ad alto rendimento nel settore sanitario.

3 titoli a dividendo su cui scommettono i migliori analisti di Wall Street

Wegovy

Health Care

Hims & Hers Health, Inc. Class A Common Stock

HIMS

I giganti farmaceutici celebrano ricavi record. Ma un&#39;insidia nel comportamento dei pazienti minaccia la crescita a lungo termine.

Farmaci anti-obesità: vendite da record, ma c&#39;è un problema

South,San,Francisco,,Ca,,Usa,-,May,1,,2022:,Merck

Long Ideas

Dividends

Gli analisti più accurati di Wall Street puntano su 3 titoli con dividendi fino al 6,7%. Le loro scelte per la difesa del portafoglio.

3 nomi del settore sanitario che pagano generosi dividendi

CVS Health Corp

Morgan Stanley ETF Trust Calvert Ultra-Short Investment Grade ETF

CARDIOVASCULAR SCI INC by Cardiovascular Sciences, Inc.

Morgan Stanley ETF Trust Calvert US Select Equity ETF

CVS Group PLC

CIVITAS SOCIAL HSG PLC by CIVITAS SOCIAL HSG PLC

CV Sciences Inc

COVISTA COMMUNS INC by Covista Communications, Inc,

Covista Communications Inc

CONVERGENCE SYS INC CL A by Convergence Systems Inc.

Convergence Systems Inc

CVS Health Corporation Says That Aetna Unveiled AI-Powered Care Paths in Health App, Giving Nurses 90 Extra Minutes Daily and Members Personalized, Simpler Access to Care

<a href="https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c">https://www.wsj.com/health/healthcare/medicare-part-d-drug-plan-premiums-set-to-rise-16ef919c</a>

General

CLOV

EHTH

ELEV

GOCO

' Medicare Part D Drug Plan Premiums Set to Rise'- WSJ

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
Wall Street rallied as a wave of new trade deals — including agreements with Japan, Indonesia, and the Philippines — fueled optimism, pushing the S&amp;P 500 and Nasdaq to fresh record highs. President Donald Trump escalated pressure on Federal Reserve Chair Jerome Powell during an in-person visit, demanding lower rates in light of trade easing.
Investor sentiment remained upbeat despite rising political friction. Treasury yields increased modestly on speculation about compromised Fed independence, amid calls from influential voices like Mohamed El‑Erian suggesting Powell resign to preserve central bank autonomy.
Looking ahead, markets are watching progress in U.S.–EU trade negotiations — including a meeting between Trump and Ursula von der Leyen — and upcoming economic data. Investor focus is also on whether pressure on the Fed may influence its rate path or institutional reputation.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46607168/google-stock-roars-as-analysts-race-to-raise-price-targets">"Google stock roars as analysts race to raise price targets"</a>, by Chris Katje, reports that Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) delivered its tenth straight quarter of earnings beats — including $96.43 billion in Q2 revenue and $2.31 EPS — prompting firms to raise their price targets on strength in AI‑driven growth across Cloud, Search, and Ads.
<a href="https://www.benzinga.com/markets/earnings/25/07/46587855/t-mobile-stock-climbs-after-q2-results-crushed-growth-records">"T‑Mobile stock climbs after Q2 results ‘crushed' growth records"</a>, by Erica Kollmann, reports that T‑Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) beat Q2 estimates with $2.84 EPS and $21.13 billion in revenue, added a record 1.7 million postpaid customers — driving upwardly revised FY2025 guidance — and sent shares higher.
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46590824/lendingtree-stock-climbs-as-company-signals-stronger-growth-ahead">"LendingTree stock climbs as company signals stronger growth ahead"</a>, by Akanksha Bakshi, reports that LendingTree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) shares rose after the company highlighted improving lead quality and customer acquisition metrics — citing momentum in core marketplaces and new verticals as drivers of expected stronger growth ahead.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/markets/earnings/25/07/46559708/capital-one-stock-climbs-on-strong-q2-eps-despite-revenue-miss">Capital One Stock Climbs On Strong Q2 EPS, Despite Revenue Miss</a>
<a href="https://www.benzinga.com/markets/earnings/25/07/46618339/coursera-stock-rockets-20-higher-after-q2-earnings-report-heres-why">Coursera Stock Rockets 20% Higher After Q2 Earnings Report: Here's Why</a>
<a href="https://www.benzinga.com/markets/earnings/25/07/46588567/quantumscape-announces-better-than-expected-q2-results-expands-collaboration-with-powerco">QuantumScape Announces Better-Than-Expected Q2 Results, Expands Collaboration With PowerCo</a>

The Bears
<a href="https://www.benzinga.com/markets/earnings/25/07/46612958/molina-healthcare-stumbles-cigna-cvs-humana">"Centene, Cigna, Others Drop As Molina's Results Rattle Sector"</a>, by Vandana Singh, reports that Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) missed Q2 earnings expectations — posting $5.48 EPS vs. $6.21 consensus — even as revenue topped estimates, and slashed its 2025 EPS guidance to just over $19 (from $21.50-$22.50), sending shares of Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and others sharply lower on concerns about medical cost trends and sector-wide risk.
<a href="https://www.benzinga.com/news/fda/25/07/46544331/fda-rejects-replimunes-blood-cancer-drug-stock-sinks">"FDA rejects Replimune's blood cancer drug, stock sinks"</a>, by Erica Kollmann, reports that Replimune Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares plunged after the FDA rejected the company's investigational oncolytic virus therapy for blood cancers, citing deficiencies in clinical data and risk-benefit analysis — prompting investor concern about future development timelines and capital needs.
<a href="https://www.benzinga.com/markets/earnings/25/07/46589727/viking-therapeutics-stock-slides-after-company-misses-q2-earnings-estimates">"Viking Therapeutics stock slides after company misses Q2 earnings estimates"</a>, by Adam Eckert, reports that Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares tumbled after reporting a Q2 loss of $0.58 per share — wider than the expected $0.46 loss — while R&amp;D expenses surged to $60.2 million and the company ended the quarter with $808 million in cash.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46606784/c3-ai-stock-is-tumbling-thursday-whats-going-on">C3 AI Stock Is Tumbling Thursday: What's Going On?</a>
<a href="https://www.benzinga.com/markets/large-cap/25/07/46641084/wall-street-stock-bubble-2025">Is A Stock Market Crash Imminent? Bubble Warnings Grow Louder</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46569958/mara-holdings-stock-is-moving-lower-wednesday-heres-why">MARA Holdings Stock Is Moving Lower Wednesday: Here's Why</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

COUR

GOOGL

MARA

REPL

TMUS

TREE

VKTX

Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets

Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) missed Wall Street expectations in its second-quarter earnings report Wednesday, triggering a selloff across the <a href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance">healthcare insurance sector</a>. 
Shares of Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>), The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Tenet Healthcare Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) all traded lower Thursday as investors reacted to Molina's earnings miss and lowered 2025 guidance, citing rising medical costs and utilization trends.
What Happened: On Wednesday after close, Molina reported second-quarter adjusted earnings of $5.48 per share, missing the consensus of $6.21 and the preliminary expectation of approximately $5.50 per share.
The insurance company reported sales&nbsp;of $11.43 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.93 billion</a>.
Molina&#8217;s second quarter results reflect a &#8220;challenging medical cost trend environment," said Joseph Zubretsky, President and Chief Executive Officer. "The current earnings pressure we are experiencing results from what we believe to be a temporary dislocation between premium rates and medical cost trend which has recently accelerated.&#8221;
Molina is still performing near its long-term target ranges, and the long-term outlook remains the same, he added.
<ul class="wp-block-list">
<li>The consolidated Medical Care Ratio (MCR) for the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46586998/molina-healthcare-reports-second-quarter-2025-financial-results" rel="noreferrer noopener">second quarter of 2025 was 90.4%</a>.</li>
<li>The Medicaid MCR was 91.3%. The company experienced medical cost pressure due to continued utilization of behavioral health, pharmacy, and inpatient and outpatient services.</li>
<li>The Medicare MCR was 90.0%, reflecting higher utilization among high-acuity members, particularly for long-term services, supports, and pharmacy.</li>
<li>The Marketplace MCR was 85.4%. Approximately 300 basis points were due to prior-year member reconciliations and a higher "new store" MCR related to the ConnectiCare acquisition.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/health-care/25/07/46396470/elevance-steps-in-as-unitedhealth-delays-will-it-set-the-tone-for-insurers" target="_blank" rel="noreferrer noopener">Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?</a>
On Wednesday, Molina further revised its 2025 earnings guidance from $21.50-$22.50 to over $19 per share.
Notably, Centene withdrew its 2025 GAAP and adjusted diluted EPS guidance. This stems from its initial review of 2025 industry data from Wakely, an <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" target="_blank" rel="noreferrer noopener">independent actuarial firm</a>.
Molina Healthcare forecasts fiscal 2025 sales&nbsp;of $44 billion compared to the consensus of $44.19 billion.
It forecasts a 2025 consolidated MCR of 90.2%, with Medicaid MCR of 90.9%, Medicare MCR of 90% and Marketplace MCR of 85.1%.
Readers should also note that the largest insurance company, UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), is also trading lower on Thursday. In an SEC filing on Thursday, the company said it has now begun complying with the Department's formal criminal and civil requests. UnitedHealth says it has full confidence in its practices and is committed to working cooperatively with the <a target="_blank" href="https://www.benzinga.com/news/legal/25/07/46605691/unitedhealth-under-federal-scrutiny-reaffirms-integrity-of-its-medicare-operations" rel="noreferrer noopener">Department throughout this process</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/restaurants/25/07/46606785/chipotle-mexican-grill-q2-sales-decline-june-july-boost-keeps-analysts-bullish" target="_blank" rel="noreferrer noopener">Chipotle Mexican Grill Q2 Sales Decline, June-July Boost Keeps Analysts Bullish</a></li>
</ul>
Image: Shutterstock

Earnings

Large Cap

Guidance

Movers

ALHC

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Centene, Cigna, Others Drop As Molina's Results Rattle Sector

WIIM

Shares of health insurers are trading lower in sympathy with Molina Healthcare, which issued soft guidance. The sector may also be under pressure after UnitedHealth said  it has now begun complying with the DOJ's formal criminal and civil requests.

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $78.5, along with a high estimate of $84.00 and a low estimate of $67.00. Witnessing a positive shift, the current average has risen by 4.83% from the previous average price target of $74.88.
<img src="https://www.benzinga.com/files/images/story/2025/1753192879_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of CVS Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$73.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CVS Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CVS Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CVS Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVS Health analyst ratings.</a>
<h2>Unveiling the Story Behind CVS Health</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
<h3>CVS Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: CVS Health's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 6.96%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CVS Health's net margin excels beyond industry benchmarks, reaching 1.88%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): CVS Health's ROE stands out, surpassing industry averages. With an impressive ROE of 2.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): CVS Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.7%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CVS Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.06, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing CVS Health: Insights From 8 Financial Analysts

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Neutral and lowers the price target from $71 to $67.

UBS Maintains Neutral on CVS Health, Lowers Price Target to $67

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.03%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and slashed the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: The Bristol Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and Pfizer alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance's patient resource, Eliquis 360 Support, on July 17.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest PFE <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="907" height="825" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272.png" alt="" class="wp-image-993503" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272-768x699.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.29%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $82 to $84 on May 12, 2025. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and raised the price target from $67 to $71 on May 2, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: CVS Health will hold a conference call on Thursday, July 31, to discuss second quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest CVS <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="922" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273.png" alt="" class="wp-image-993506" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273-768x698.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.47%</li>
<li>Citigroup analyst Geoff Meacham downgraded the stock from Buy to Neutral and cut the price target from $210 to $205 on May 14, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Guggenheim analyst Vamil Divan maintained a Buy rating and increased the price target from $214 to $216 on April 29, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: GI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie, on July 10, announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest ABBV <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="910" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274.png" alt="" class="wp-image-993508" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274-768x699.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Shares of health insurers are trading lower amid a selloff in the sector following Elevance's recent soft guidance and broader concerns over rising medical costs.

<a href="https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c" title="https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c">https://www.wsj.com/health/healthcare/obamacare-insurers-seek-double-digit-premium-hikes-next-year-454f1e1c</a>

Biotech

Reported Earlier: 'Obamacare Insurers Seek Double-Digit Premium Hikes Next Year; Some Enrollees Could Be Hit With Increases Of More Than 20% Because Of Federal Changes And Higher Health Expenses' - WSJ Exclusive

https://www.nytimes.com/2025/07/18/health/health-insurance-prescription-claim-denials.html#:~:text=Prescription%20drug%20denials%20by%20private,nation's%20private%20health%20insurance%20system.

Reported Earlier: 'Health Insurers Are Denying More Drug Claims, Data Shows' - NY Times

Shares of health insurance stocks are trading lower in sympathy with Elevance Health after the company reported mixed Q2 financial results and cut its FY25 adjusted EPS guidance.

CVS Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has risen 21.14% since its last report. The company recently reported that it has 18.71 million shares sold short, which is 1.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.14 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752080444_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CVS Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 10.36%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is CVS Health Gaining or Losing Market Support?

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its head above parity. Nevertheless, the statistical winds may point to an eventual recovery which options traders could potentially exploit.
Fundamentally, in the post-pandemic era, sentiment toward Eli Lilly skyrocketed thanks to its <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">weight-loss drug</a>. In 2023, the U.S. Food and Drug Administration (FDA) approved the Zepbound (tirzepatide), the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. An injectable prescription medication that helps adults with other weight-related problems, Zepbound's clinical trials showed promising results.
Thanks to this early success, Eli Lilly and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) effectively formed a duopoly in the weight-loss market. While this reality contributed to a significant valuation surge, competition started to heat up last year. With major pharmaceuticals like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Roche Holding Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announcing advancements in the <a href="https://www.benzinga.com/general/biotech/24/07/39849867/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-wont-be-dominated-by-just-2">development of obesity-fighting drugs</a>, LLY stock entered into a frustrating consolidation channel.
Still, with the pharmaceutical giant incurring an extended period of red ink in the market, JPMorgan analyst Chris Schott is essentially making the case that Eli Lilly is undervalued. Specifically, prescriptions for Zepbound and Mounjaro (an injectable <a href="https://www.lilly.com/news/media/media-kits/mounjaro">medicine</a> for adults with type 2 diabetes) are running ahead of expectations in the second quarter. As such, this performance may allow the pharmaceutical to beat and raise guidance throughout 2025.
Even with the <a href="https://www.benzinga.com/content/45261458/is-eli-lilly-a-buy-after-weak-earnings-and-cvs-novo-partnership">formulary change</a> by CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) putting around 200,000 patients at risk of losing access, Schott states that Eli Lilly's market share — which stands at about 70% to 75% of new patients — and strong momentum may help the company easily absorb the impact.
<h2 class="wp-block-heading">Statistical Backdrop Could Point To A Recovery In LLY Stock</h2>
Although the fundamental narrative of LLY stock is intriguing, it may also be a presuppositional leap. Essentially, the conclusion that LLY is undervalued is already embedded in the premise (that the market is not fully pricing in the good news for Eli Lilly).
If one thinks about it, it's an extraordinary claim. LLY stock routinely ranks among the most actively traded securities. That the market is somehow mispricing the pharmaceutical giant is an assertion that requires extraordinary evidence. In my opinion, if such evidence exists, it will likely materialize in the statistical realm as it's the arena that few (if any) analysts venture into.
A significant barrier to statistical analysis of the financial markets is the deployment of continuous scalar signals, such as share price or various valuation ratios. Because these signals are non-stationary, it's difficult (if not outright impossible) to extract meaningful insights based on the frequency of past analogs. Especially for highly traded securities like LLY stock, the measurement metrics constantly fluctuate.
To remedy this problem, we can impose stationarity by converting scalar signals into discrete states. For analyzing securities, converting share price into market breadth or sequences of accumulative and distributive sessions carries significant advantages. First, market breadth is essentially a representation of demand and demand is effectively binary. Second, clusters of binary codes can form distinct behavioral states, which can then serve as past analogs for extracting forward probabilities.
As an example, in the trailing two months, the price action of LLY stock can be interpreted as a "6-4-D" sequence: six up weeks, four down weeks, with a negative trajectory across the 10-week period. Admittedly, this process pancakes LLY's magnitude dynamism into a simple binary code. But the benefit is that this code can be easily segregated into distinct market profiles. From there, we can observe the likelihood of transition from one state to another.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-975331" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
With the above framework, we can identify that since January 2019, the 6-4-D sequence has materialized 38 times. From past analogs, we can also determine that in 68.42% of cases, the following week's price action results in upside, with a median return of 2.47%.
Accounting for the volatility on Monday, a realistic target over the next three weeks — assuming that the bulls gain and maintain control of the market — is just under the $800 level.
<h2 class="wp-block-heading">Playing The Odds With Eli Lilly</h2>
Based on the market intelligence above, bold speculators may consider the 785/790 bull call spread expiring Aug. 1. This transaction involves buying the $785 call and simultaneously selling the $790 call, for a net debit paid of $255 (the most that can be lost in the trade). Should LLY stock rise through the short strike price ($790) at expiration, the maximum reward is $245, a payout of 96%.
To be sure, the 780/790 bull spread expiring on the same day offers a payout of nearly 113%. However, the net debit required is $470, which puts significantly more capital at risk for only a modest increase in payout. Therefore, the 785/790 call spread is arguably more tempting.
Either way, both transactions require LLY stock to hit or exceed $790 on Aug. 1, which empirically appears to be a reasonable target. As a baseline, the chance that a long position in LLY will be profitable on any given week is quite high at 60.29%. However, the market's response to the 6-4-D sequence amplifies the odds in favor of the bullish speculator, thus incentivizing a debit-based strategy.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46253955/khc-stock-bearish-pressure-statistical-reversal">Options Corner: Why Kraft Heinz Could Flip The Script On The Bears</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Options

RHHBY

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand.
What Happened: The medications cost around $500 monthly for uninsured patients, while insured coverage remains inconsistent across plans. &#8220;Coverage is not the same as access,&#8221; said Beverly Tchang, a New York-based physician who advises both Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), reported <a href="https://apnews.com/article/wegovy-zepbound-obesity-drugs-coverage-access-142e234c16df4443e8f66c27d01f44e2#">the</a> Associated Press.
GLP-1 receptor agonists continue driving substantial revenue for both drugmakers. Zepbound generated $2.3 billion in U.S. first-quarter sales, while Wegovy contributed nearly $1.9 billion with approximately 200,000 weekly prescriptions domestically.
Insurance coverage varies dramatically by provider and plan type. Novo Nordisk reports that 85% of covered U.S. patients pay $25 or less monthly. However, most state Medicaid programs and Medicare exclude obesity coverage, forcing patients to shoulder hundreds in out-of-pocket costs monthly, according to the report.
See Also: <a href="https://www.benzinga.com/markets/large-cap/25/07/46269182/ai-assistants-could-break-amazons-60-billion-retail-media-business-warns-vc-its-not-just-search-at-google-its-search-everywhere">AI Assistants Could Break Amazon&#8217;s $60 Billion Retail Media Business, Warns VC: &#8216;It&#8217;s Not Just Search At Google — It&#8217;s Search Everywhere&#8217;</a>
Why It Matters: The regulatory landscape remains complex regarding compounded versions. Despite FDA determinations that drug shortages ended, compounding pharmacies continue selling cheaper alternatives under personalization exceptions.
Hims &amp; Hers Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) offers compounded semaglutide starting at $165 monthly, leading to legal challenges from Eli Lilly.
Recent pricing trends show that both companies reduced uninsured patient costs by several hundred dollars from initial launch prices. However, $500 monthly represents approximately 14% of the average U.S. per-capita income at $43,000 annually.
Long-term adherence data reveals persistence challenges that could impact market expansion. Real-world studies show only 8.1% of patients maintained GLP-1 obesity therapy after three years, though one-year persistence for Wegovy <a href="https://www.benzinga.com/news/health-care/25/06/46102213/us-adults-struggle-with-long-term-use-of-obesity-drugs-like-wegovy-data-shows">improved from 33.2% in 2021 to 62.7% in 2024</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46268630/alphabet-backed-drug-discovery-firm-nears-human-trials-of-ai-developed-remedies-says-president-the-next-big-milestone-is">Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: &#8216;The Next Big Milestone Is…&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Tobias Arhelger / Shutterstock.com

Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: 'Coverage Is Not The Same As Access,' Says Expert

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.79%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On June 26, Pfizer announced positive topline Phase 3 results for HYMPAVZI&#x2122; in Hemophilia A or B with inhibitors.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">latest PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="917" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39.png" alt="" class="wp-image-971905" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03065950/image-39-768x688.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.99%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $82 to $84 on May 12, 2025. This analyst has an accuracy rate of 67%.</li>
<li>RBC Capital analyst Ben Hendrix maintained an Outperform rating and boosted the price target from $74 to $81 on May 5, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: CVS Health will hold a conference call on Thursday, July 31 to discuss second quarter 2025 financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">CVS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="912" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40.png" alt="" class="wp-image-971907" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070012/image-40-768x696.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.93%</li>
<li>Citigroup analyst Andrew Baum downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating with a price target of $115 on April 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On July 2, the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for Merck's new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for Winrevair (sotatercept-csrk).</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest MRK <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0703"><img loading="lazy" decoding="async" width="911" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41.png" alt="" class="wp-image-971910" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03070051/image-41-768x697.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Across the recent three months, 10 analysts have shared their insights on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CVS Health, presenting an average target of $79.0, a high estimate of $84.00, and a low estimate of $71.00. This upward trend is evident, with the current average reflecting a 8.97% increase from the previous average price target of $72.50.
<img src="https://www.benzinga.com/files/images/story/2025/1751310042_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive CVS Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to CVS Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CVS Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CVS Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVS Health analyst ratings.</a>
<h2>Get to Know CVS Health Better</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
<h3>CVS Health: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining CVS Health's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.96% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CVS Health's net margin excels beyond industry benchmarks, reaching 1.88%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.33%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CVS Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.7%, the company may face hurdles in achieving optimal financial performance.
Debt Management: CVS Health's debt-to-equity ratio stands notably higher than the industry average, reaching 1.06. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: CVS Health Through The Eyes Of 10 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>B of A Securities raised Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) price target from $20 to $23. B of A Securities analyst Wamsi Mohan maintained a Buy rating. Hewlett Packard Enterprise shares closed at $18.41 on Friday. <a href="https://www.benzinga.com/quote/HPE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS cut the price target for United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from $410 to $385. UBS analyst Ashwani Verma maintained a Buy rating. United Therapeutics shares closed at $284.27 on Friday. <a href="https://www.benzinga.com/quote/UTHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital slashed Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) price target from $7 to $3. BMO Capital analyst John McNulty downgraded the stock from Market Perform to Underperform. Tronox shares closed at $5.64 on Friday. <a href="https://www.benzinga.com/quote/TROX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup boosted the price target for Air Products and Chemicals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) from $310 to $320. Citigroup analyst Patrick Cunningham maintained a Buy rating. Air Products shares closed at $282.35 on Friday. <a href="https://www.benzinga.com/quote/APD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays increased the price target for Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from $67 to $80. Barclays analyst Ramsey El-Assal maintained an Overweight rating. Affirm Holdings shares closed at $68.06 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) price target from $81 to $85. Raymond James analyst RJ Milligan maintained an Outperform rating. Boyd Gaming shares settled at $79.02 on Friday. <a href="https://www.benzinga.com/quote/BYD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) price target from $100 to $120. JP Morgan analyst Cory Carpenter maintained an Overweight rating. Roblox shares closed at $105.59 on Friday. <a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) price target from $74 to $80. Jefferies analyst Brian Tanquilut maintained a Buy rating. CVS Health shares closed at $68.49 on Friday.  <a href="https://www.benzinga.com/quote/CVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities boosted the price target for J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) from $130 to $140. Truist Securities analyst Lucas Pipes maintained a Hold rating. J.B. Hunt Transport shares settled at $145.34 on Friday. <a href="https://www.benzinga.com/quote/JBHT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim increased The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) price target from $120 to $140. Guggenheim analyst Michael Morris maintained a Buy rating. Disney shares closed at $122.34 on Friday. <a href="https://www.benzinga.com/quote/dis/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DIS/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447-1024x587.png" alt="" class="wp-image-967350" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30132946/image-447.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/46136470/jim-cramer-just-revealed-1-oil-stock-he-actually-wants-to-own">Jim Cramer Just Revealed 1 Oil Stock He Actually Wants To Own</a> </li>
</ul>
Photo via Shutterstock

AFRM

JBHT

RBLX

TROX

UTHR

Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday

Jefferies analyst Brian Tanquilut maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $74 to $80.

Jefferies Maintains Buy on CVS Health, Raises Price Target to $80

<a href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/" title="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/</a>
&nbsp;

'US Supreme Court preserves key element of Obamacare preventive care'- Reuters

Press Releases

CVS Health to hold second quarter 2025 earnings conference call

Synergy CHC Corp. (NASDAQ: SNYR) Secures Distribution Wins for FOCUSfactor® Supplements and Functional Beverages – More Stocks Inside

Synergy's (NASDAQ: SNYR) "FOCUSfactor" Massive 50,000 Store Expansion Including Walmart (NYSE: WMT) Canada – Alongside MOGO, ELWS, DAIC – Stocks Under $5 to Watch

CVS Health declares quarterly dividend

EngageWell, Rocket Doctor, and CVS Health Foundation Launch Virtual Healthy Aging Program for Adults over 60

Multi-Billion Virtual Healthcare Industry Witnessing Substantial Growth with Rapid Expansion Expected

Synergy (NASDAQ: SNYR) Strategic Partnership w/ McKesson (NYSE: MCK) Sends "FOCUSfactor" Exploding Across North America – More Stocks Inside

Tech Momentum Surges as IPA, HIT, SNYR, PNPN.V, KAPA and Others Drive Investor Awareness – More Stocks Inside

CVS Health opens new Workforce Innovation and Talent Center in Columbus

Aetna Launches New AI and Digital Tools to Improve Access and Care

AMZN

ARTL

BMNR

COST

CSE:TRUE

DAIC

DARE

ELWS

IPDN

KAPA

MOGO

PLRZ

PLUG

PNPNF

PRSO

SNYR

TDOC

TREIF

TSXV:PNPN

WBUY

WOLF

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
03:41 PMJul 28, 2025	PUT	$60.00	Sep 19, 2025	49	4476	4250	32	14089	TRADE	BEARISH
02:42 PMJul 23, 2025	CALL	$65.00	Jan 15, 2027	532	682	666	20	3386	SWEEP	BULLISH

Comments

CVS Health

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO